Details

Autor(en) / Beteiligte

• Walter, Emmanuel B
• Talaat, Kawsar R
• Sabharwal, Charu
• Gurtman, Alejandra
• Lockhart, Stephen
• Paulsen, Grant C
• Barnett, Elizabeth D
• Muñoz, Flor M
• Maldonado, Yvonne
• Pahud, Barbara A
• Domachowske, Joseph B
• Simões, Eric A.F
• Sarwar, Uzma N
• Kitchin, Nicholas
• Cunliffe, Luke
• Rojo, Pablo
• Kuchar, Ernest
• Rämet, Mika
• Munjal, Iona
• Perez, John L
• Frenck, Robert W
• Lagkadinou, Eleni
• Swanson, Kena A
• Ma, Hua
• Xu, Xia
• Koury, Kenneth
• Mather, Susan
• Belanger, Todd J
• Cooper, David
• Türeci, Özlem
• Dormitzer, Philip R
• Şahin, Uğur
• Jansen, Kathrin U
• Gruber, William C

Titel

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age

Ist Teil von

• The New England journal of medicine, 2022-01, Vol.386 (1), p.35-46

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2022

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• After a dose for further testing was determined in a phase 1 study, a phase 2–3 trial was initiated in which two 10-μg doses of BNT162b2 were given 21 days apart to children 5 to 11 years of age. No serious adverse events were observed. High levels of neutralizing antibodies were induced, and vaccine efficacy 7 days or more after the second dose was 90.7%.